The aim is to present current and new strategies university hospitals can undertake to contain costs of expensive drugs using a drug life cycle approach.
To explore and implement strategies for optimizing healthcare resource utilization in oncology, with the aim of advancing the (financial) sustainability in oncology care.
My research focuses on the occurence of nocebo-effects in statin-intolerant. We try to identify patients who are statin-intolerant and that suffer from these effects. We hope that by identifying patients affected by the nocebo effect and allowing them to experientially understand its impact through an N=1 study design, they will experience fewer side effects from their statin treatment. This may help prevent the need to switch to expensive PCSK9 inhibitors.
Cost benefit analysis clinical medication reviews. Follow up of interventions from clinical pharmacists. Medication information needs of hospitalized patients.
Hospital expenditure of expensive drugs increases yearly. In addition, shortages are becoming more common. To assure access to healthcare and treatment in the future, sustainable use of expensive drugs is very important. This research aims to optimize treatment with regard to efficacy and safety, while aiming to reduce drug costs.